Top 10 New Entrants companies in PCSK9 Inhibitors by Most Patent Filing In 3 Years in the world in 2020 – Discovery

Free Trial

The PCSK9 Inhibitors top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 3 Years PCSK9 Inhibitors New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2020, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

Ranking Year:

Region:

Ranking:

1	Novo Nordisk A/S	Hovedstaden, Denmark	Insulin,Health care,Haemophilia, ...[+2]	Patent: 24
2	AstraZeneca UK Ltd.	Cambridgeshire, United Kingdom	Gastrointestinal infections,Medicine,Simvastatin, ...[+2]	Patent: 12
3	AstraZeneca Plc	Cambridgeshire, United Kingdom	Medicine,Health care,Side effect, ...[+2]	Patent: 12
4	Novartis AG	Basel-Stadt, Switzerland	Dosage form,Health care,Medicine, ...[+2]	Patent: 11
5	Shenzhen Salubris Pharmaceuticals Co., Ltd.	Guangdong Sheng, China	Medicine,Cefaclor,Antithrombotic, ...[+2]	Patent: 5
6	The Brigham & Women's Hospital, Inc.	Massachusetts, United States	Health care,Mitral valve surgery,Health equity, ...[+2]	Patent: 5
7	Duke University	North Carolina, United States	Style guide,Typeface,Medicine, ...[+2]	Patent: 4
8	STARTUP Dogma Therapeutics, Inc.	Massachusetts, United States	PCSK9,Cardiovascular agent,Biophysics, ...[+2]	Patent: 3
9	Institut National de la Santé et de la Recherche Médicale	Île-de-France, France	Public health,Genomics,Antisense therapy, ...[+2]	Patent: 3
10	Ra Pharmaceuticals, Inc.	Massachusetts, United States	Medicine,Health care,Drug class, ...[+2]	Patent: 3